Global HPV Testing Market 2015-2019 - Increased Incidence of HPV Drives Market

News provided by

Research and Markets

16 Jul, 2015, 15:41 GMT

DUBLIN, July 10, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/2s2746/global_hpv) has announced the addition of the "Global HPV Testing Market 2015-2019" report to their offering.

Continue Reading
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

The global HPV testing market to grow at a CAGR of 16.17% over the period 2014-2019.

HPV refers to a group of more than 200 related viruses commonly causing infections that do not have any symptoms. Among these, more than 40 types of HPV cause highly contagious diseases that are transmitted through direct sexual contact, infecting both male and female genitals. The other types of HPV cause non-genital warts that are not sexually transmitted. Though most HPV infections are harmless and heal on their own, certain high-risk types of genital HPV can be persistent and cause cervical, penile, anal, vaginal, and oropharyngeal cancers. Many individuals undergo regular HPV tests as a preventive measure. HPV tests help detect the viral genetic material in a cell sample taken from the cervix.

To calculate the market size, The author uses revenue generated from the sales of HPV testing kits and detection systems. The report includes the segmentation of the market based on the following three regions: the Americas, APAC, and EMEA.

HPV and Pap tests help detect cervical cancer in women. The Pap test identifies changes in cervical cells caused by HPV infection. The HPV test is used to check for HPV DNA in sample cells. A physician may advise a patient to undergo both HPV and Pap tests for the screening of cervical cancer. The American Cancer Society, the US Preventive Services Task Force, the American Society for Clinical Pathology, and the American Society for Colposcopy and Cervical Pathology have provided guidelines for the testing of cervical cancer in women in the US. These guidelines state that women aged between 30 and 65 should undergo Pap and HPV co-testing every five years or get a Pap test every three years.

According to the report, HPV is the most widespread STD in both men and women. The infection can lead to cervical, vulvar, or vaginal cancer in women and penile cancer in men. In the US, about 20-million people are currently affected with HPV, and more than six-million individuals become infected each year. Research has revealed that HPV is commonly transmitted through unprotected sexual contact. Factors such as contact with infected skin, genital fluids, or lesions are responsible for the development of HPV infections. The low-risk infection does not lead to cancer, but it can cause condylomata acuminata on or around the genitals, anus, mouth, or throat. For instance, HPV types 6 and 11 account for 90% of genital warts. The high-risk infection, especially HPV types 16 and 18, is responsible for most HPV-related cancers.

Further, the report states that a lack of awareness of HPV and its diagnostic kits among people has a negative impact on market growth.

Key Vendors

  • Abbott Diagnostics
  • Hologic
  • Qiagen
  • Roche Diagnostics

Other Prominent Vendor

  • Arbor Vita
  • Becton, Dickinson and Company
  • Cepheid
  • Delphi Bioscience
  • DiaCarta
  • Diasorin
  • Fujirebio
  • Genera Biosystems
  • IncellDx
  • OralDNA Labs
  • Quest Diagnostics
  • Seegene
  • Trovagene
  • Ventana Medical Systems

For more information visit http://www.researchandmarkets.com/research/2s2746/global_hpv

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com